http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer.
Chae, Yee Soo,Kim, Jong Gwang,Lee, Soo Jung,Kang, Byung Woog,Lee, Yoo Jin,Park, Jae Yong,Jeon, Hyo-Sung,Park, Jun Seok,Choi, Gyu Seog Potamitis Press 2013 Anticancer research Vol.33 No.8
<P>Recent evidence suggests that the rs2910164 variant of miR-146a is associated with the development of certain types of cancer. Therefore, the aim of this study was to investigate the association of this genetic variant with susceptibility and prognosis in patients with colorectal cancer (CRC).</P>
Functional polymorphism in the MicroRNA-367 binding site as a prognostic factor for colonic cancer.
Chae, Yee Soo,Kim, Jong Gwang,Kang, Byung Woog,Lee, Soo Jung,Lee, Yoo Jin,Park, Jun Seok,Choi, Gyu Seog,Lee, Won Kee,Jeon, Hyo-Sung Potamitis Press 2013 Anticancer research Vol.33 No.2
<P>As microRNAs play important roles in cancer development and progression by regulating the expressions of oncogenes and tumor suppressor genes though interacting with the 3' untranslated region (UTR) of target genes, we aimed to evaluate the association between genetic variants of miRNAs and their binding sites and prognosis in patients with colorectal cancer (CRC).</P>
PPP1R13L variant associated with prognosis for patients with rectal cancer.
Chae, Yee Soo,Kim, Jong Gwang,Kang, Byung Woog,Lee, Soo Jung,Jeon, Hyo-Sung,Park, Jun Seok,Choi, Gyu Seog,Lee, Won Kee Springer-Verlag 2013 Journal of cancer research and clinical oncology Vol.139 No.3
<P>ERCC1, CD3EAP, and PPP1R13L polymorphisms in the chromosomal region 19q13.2-3 have already been shown to have a synergistic effect on apoptosis and DNA repair pathways. Therefore, the aim of this study was to investigate the association between such genetic variants and the prognosis of colorectal cancer (CRC) following curative surgery.</P>
Chae, Yee Soo,Kim, Jong Gwang,Sohn, Sang Kyun,Cho, Yoon Young,Ahn, Byung Min,Moon, Joon Ho,Jeon, Seoung Woo,Park, Jae Yong,Lee, In Taek,Choi, Gyu Seog,Jun, Soo-Han The Korean Academy of Medical Sciences 2008 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.23 No.3
<P>Since vascular endothelial growth factor (VEGF) is known to be a potent pro-angiogenic factor, we evaluated the potential association of two <I>VEGF</I> gene polymorphisms (-634G>C and 936C>T) with the susceptibility and the clinicopathologic characteristics of colorectal cancer (CRC). The <I>VEGF</I> genotypes were determined using fresh colorectal tissue from 465 patients who had undergone a surgical resection and peripheral blood lymphocytes from 413 healthy controls by PCR/DHPLC assay. For the -634G>C polymorphism, the -634 GC or CC genotype was associated with a decreased risk of CRC (odds ratio [OR], 0.62; <I>p</I>=0.001) as a dominant model of C allele, whereas the 936 TT genotype correlated with advanced stage/ metastasis, a high serum level of CA19-9, and an higher grade in patients with CRC. In the haplotype analyses, haplotype -634C/936C and -634G/936T were associated with a decreased susceptibility of CRC (OR, 0.53 and 0.56; <I>p</I><0.001, respectively). These observations imply that the <I>VEGF</I> gene polymorphisms may be associated with the susceptibility or clinicopathologic features of CRC. However, further studies of other <I>VEGF</I> sequence variants and their biological functions are needed to understand the role of the <I>VEGF</I> gene polymorphisms in the development and progression of CRC.</P>
Chae, Yee Soo,Kim, Jong Gwang,Sohn, Sang Kyun,Cho, Yoon Young,Moon, Joon Ho,Bae, Han-Ik,Park, Jae Yong,Lee, Myung-Hoon,Lee, Hyun-Chul,Chung, Ho Young,Yu, Wansik S. Karger AG 2007 Oncology Vol.71 No.3
<P><I>Objective:</I> Vascular endothelial growth factor (VEGF) is known to be a potent proangiogenic factor. This study evaluates the potential association of three VEGF gene polymorphisms (-460T > C, +405G > C, and 936C > T) with the susceptibility to and clinicopathologic characteristics of gastric cancer. <I>Methods:</I> The VEGF genotypes were determined using paraffin-embedded tissue from 413 patients who underwent a surgical resection and peripheral blood lymphocytes from 413 healthy controls by PCR-RFLP assay. <I>Results:</I> There was no difference in the allele frequency of -460T > C polymorphism. However, for the +405G > C polymorphism, the +405C allele was associated with a significantly decreased susceptibility to gastric cancer [odds ratio (OR) 0.686; 95% confidence interval (CI) 0.564-0.834]. Although there was no significant difference in the distribution of the 936C > T polymorphism between the two groups, the 936T allele was associated with a decreased susceptibility to gastric cancer (OR 0.757; 95% CI 0.591-0.970). In the haplotype analyses, the haplotype TCT (OR 0.405; 95% CI 0.263-0.624) was most closely associated with a decreased susceptibility to gastric cancer. However, no significant association was observed between the frequency of the genotypes or alleles and the clinicopathologic characteristics of gastric cancer. <I>Conclusion:</I> These observations imply that the VEGF gene polymorphisms may be associated with the susceptibility to gastric cancer. However, further studies of other VEGF sequence variants and their biological functions are needed to understand the role of the VEGF polymorphisms in determining the susceptibility to gastric cancer.</P><P>Copyright © 2006 S. Karger AG, Basel</P>
Clinical Significance of Autoantibody Expression in Allogeneic Stem-Cell Recipients
Moon, Joon-Ho,Lee, Soo-Jung,Kim, Jong-Gwang,Chae, Yee-Soo,Kim, Shi-Nae,Kang, Byung-Woog,Suh, Jang-Soo,Lee, Kun-Soo,Sohn, Sang-Kyun Lippincott Williams Wilkins, Inc. 2009 Transplantation Vol.88 No.2
BACKGROUND.: The occurrence of autoantibodies has been reported in allogeneic stem-cell recipients, but the association of this occurrence with chronic graft-versus-host disease (cGVHD) or survival remains uncertain. METHODS.: A total of 121 consecutive patients who underwent allogeneic stem-cell transplantation from November 2001 to March 2008 and survived at least 3 months after transplantation were included in this study. RESULTS.: Forty-seven patients (38.8%) expressed at least one of various autoantibodies after transplantation. Antinuclear antibody was positive in 22 patients (18.2%), antidouble stranded DNA in seven (5.8%), antismooth muscle antibody in six (5%), rheumatoid factor in 17 (14.0%), and a positive Coombs test recorded for 12 patients (9.9%). cGVHD was more commonly diagnosed in the patients with autoantibody expression (61.7% vs. 43.2%, P=0.048). The patients expressing autoantibodies had a better 5-year overall survival than those without any autoantibody expression: 70.2% and 47.9% for the autoantibody-positive and autoantibody-negative patients, respectively (P=0.002). The cumulative incidence of relapse was 21.5% and 39.3% for the autoantibody-positive and autoantibody-negative patients, respectively (P=0.023). In particular, the patients expressing autoantibodies without cGVHD had a better overall survival (100%) than the patients in the other groups: 63.1% for the autoantibody- and cGVHD-positive patients, 59.6% for the autoantibody-negative and cGVHD-positive patients, and 36.6% for the autoantibody- and cGVHD-negative patients. The multivariate analysis identified autoantibody expression as a good prognostic factor regarding survival (hazard ratio=0.378, 95% confidence interval=0.185–0.775, P=0.008). CONCLUSION.: The occurrence of autoantibodies after allogeneic stem-cell transplantation was found to be related to cGVHD, and patients expressing autoantibodies had a better survival.
Kim, Shi Nae,Moon, Joon Ho,Kim, Jong Gwang,Chae, Yee Soo,Cho, Yoon Young,Lee, Soo Jung,Kim, Yun Jeong,Lee, Yoo Jin,Suh, Jang Soo,Lee, Kun Soo,Sohn, Sang Kyun Wiley Subscription Services, Inc., A Wiley Company 2009 JOURNAL OF CLINICAL APHERESIS Vol.24 No.5
<P>The effects of GM-/G-CSF and darbepoetin-α on stem cell mobilization were investigated. From February 2005 to March 2007, 30 allogeneic sibling donors were randomly assigned to a G-CSF group (5 μg/kg/day for 5–7 days) or triple group (GM-CSF 10 μg/kg/day on 1st and 2nd day, G-CSF 5 μg/kg/day for 5–7 days, and darbepoetin-α 40 mg on 1st day). The MNCs and CD34<SUP>+</SUP> cells were not different between the two groups, although the doses (×10<SUP>8</SUP>/kg of recipient body weight) of CD3<SUP>+</SUP> cells (3.64 ± 1.75 vs. 2.63 ± 1.36, P = 0.089) and CD8<SUP>+</SUP> cells (1.07 ± 0.53 vs. 0.60 ± 0.30, P = 0.006) were lower in the triple group. The engraftments, frequency of RBC transfusions, and hemoglobin recovery were not different between the two groups. The cumulative incidence of overall and Grades II–IV aGVHD was 64.3% vs. 61.1% and 25.9% vs. 27.1% in the G-CSF and triple regimen group, respectively, whereas the cumulative incidence of cGVHD was 20.8 ± 1.3% and 24.4 ± 1.7%, respectively. In conclusion, the triple regimen did not seem to be superior to G-CSF alone in terms of the CD34+ cell dose, hemoglobin recovery, and GVHD. However, the CD8+ cell count was significantly lower in the triple regimen group. The role of a lower CD8+ cell count in the graft may need to be elucidated in the future. J. Clin. Apheresis, 2009. © 2009 Wiley-Liss, Inc.</P>